Zhang Ling, Wang Ting-li, Zhao Yu-liang, Chen Zhi-wen, Tang Yi, Yang Ying-ying, Liao Yu-jie, Fu Ping
Department of Nephrology, West China Hospital, Sichuan University, Chengdu 610041, China.
Zhonghua Nei Ke Za Zhi. 2013 Jun;52(6):459-63.
To evaluate the safety and efficacy of regional citrate anticoagulation in sustained low efficiency dialysis (SLED).
A total of 45 patients with acute kidney injury (AKI) or end stage renal disease (ESRD) admitted in our hospital from August 2011 to September 2012 were prospectively enrolled in this study. All the patients received SLED treatment by Fresenius 4008sARrTplus dialyzer through either femoral or internal jugular venous catheter, with each session of SLED treatment lasting for 8 hours. All the patients were pumped in 4% tri-sodium citrate solution through the arterial line at 130 ml/hour and 10% calcium gluconate through the venous line at 40 ml/hour. The blood flow was 150 ml/minute while the calcium-free dialysate was delivered at 200 ml/minute. Systemic citrate concentration, peripheral and post dialyzer ionized calcium levels at 0, 2 and 5 hour were recorded.
All the 45 patients underwent 162 sessions of SLED with 2 were discontinued due to III° dialyzer coagulation, and other 160 SLED sessions (98.8%) were all successfully performed. The systemic citrate concentration at 0 hour was (0.14 ± 0.06) mmol/L, the systemic citrate concentrations at 2 and 5 hour were slightly increased while no statistical difference was found[(1.08 ± 0.12) mmol/L vs (1.11 ± 0.17) mmol/L, P > 0.05]. The 0, 2, 5 hour peripheral blood ionized calcium levels were (1.04 ± 0.13) mmol/L, (1.07 ± 0.23) mmol/L and (1.04 ± 0.24) mmol/L, respectively, with no significant difference (P > 0.05). The post dialyzer ionized calcium levels were (0.31 ± 0.04) mmol/L at 2 hour and (0.29 ± 0.03) mmol/L at 5 hour. The transmembrane pressure at 2 hour was (104.5 ± 17.8) mm Hg(1 mm Hg = 0.133 kPa), and (109.3 ± 20.1) mm Hg at 5 hour, however the increase was not of statistical significance (P > 0.05). At 5 hour, prothrombin time and activated partial thrombin time were identified to be similar to those before SLED. During the treatments, no bleeding complication, thrombocytopenia, cardiac arrhythmia, hypernatremia, metabolic alkalosis or hypotension was observed.
SLED under regional citrate anticoagulation is safe and effective. Citrate achieves satisfying regional anticoagulation effect without interfering systemic clotting function, thus this study provides a new option of SLED anticoagulation for clinicians.
评估局部枸橼酸抗凝在持续性低效透析(SLED)中的安全性和有效性。
前瞻性纳入2011年8月至2012年9月我院收治的45例急性肾损伤(AKI)或终末期肾病(ESRD)患者。所有患者均通过费森尤斯4008sARrTplus透析器经股静脉或颈内静脉置管进行SLED治疗,每次SLED治疗持续8小时。所有患者经动脉管路以130 ml/小时的速度泵入4%枸橼酸钠溶液,经静脉管路以40 ml/小时的速度泵入10%葡萄糖酸钙。血流量为150 ml/分钟,无钙透析液流速为200 ml/分钟。记录0、2和5小时的全身枸橼酸浓度、外周血和透析器后离子钙水平。
45例患者共进行了162次SLED治疗,其中2次因Ⅲ级透析器凝血而中断,其余160次SLED治疗(98.8%)均成功完成。0小时全身枸橼酸浓度为(0.14±0.06)mmol/L,2小时和5小时全身枸橼酸浓度略有升高,但差异无统计学意义[(1.08±0.12)mmol/L vs(1.11±0.17)mmol/L,P>0.05]。0、2、5小时外周血离子钙水平分别为(1.04±0.13)mmol/L、(1.07±0.23)mmol/L和(1.04±0.24)mmol/L,差异无统计学意义(P>0.05)。透析器后2小时和5小时离子钙水平分别为(0.31±0.04)mmol/L和(0.29±0.03)mmol/L。2小时跨膜压为(104.5±17.8)mmHg(1 mmHg = 0.133 kPa),5小时为(109.3±20.1)mmHg,但升高无统计学意义(P>0.05)。5小时时,凝血酶原时间和活化部分凝血活酶时间与SLED治疗前相似。治疗期间,未观察到出血并发症、血小板减少、心律失常、高钠血症、代谢性碱中毒或低血压。
局部枸橼酸抗凝的SLED安全有效。枸橼酸可实现满意的局部抗凝效果,而不干扰全身凝血功能,因此本研究为临床医生提供了一种新的SLED抗凝选择。